查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
支气管炎治疗的全球市场:现状分析与预测(2021年～2027年)
市场调查报告书
商品编码
1096539

支气管炎治疗的全球市场:现状分析与预测(2021年～2027年)

Bronchitis Treatment Market: Current Analysis and Forecast (2021-2027)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球支气管炎治疗的市场规模在预测期间(2021年～2027年)中预计将以约5％的年复合成长率成长。

哮喘、慢性阻塞性肺病和肺癌等呼吸道疾病的患病率不断上升，加上人口老龄化的加剧，预计将推动对支气管炎治疗的需求，并推动支气管炎治疗市场的增长。预计吸烟人口的迅速增加也将增加对支气管炎治疗的需求。

本报告提供全球支气管炎治疗市场的相关调查，提供市场洞察，市场趋势，竞争模式，企业概要等全面性资讯。

目录

第1章 市场简介

  • 市场定义
  • 限制
  • 相关利益者
  • 报告所使用的货币

第2章 调查方法或假设

  • 支气管炎治疗市场调查流程
  • 支气管炎治疗市场调查手法
  • 预测方法
  • 受访者简介
  • 支气管炎治疗市场调查的主要目的

第3章 市场摘要

第4章 摘要整理

第5章 支气管炎治疗市场上COVID-19影响

第6章 支气管炎治疗市场收益(10亿美元)(2019年～2027年)

第7章 市场洞察:各类型

  • 急性支气管炎
  • 慢性支气管炎

第8章 市场洞察:各类药物

  • 抗生素
  • 抗发炎药
  • 支气管扩张药
  • 其他

第9章 市场洞察:各流通管道

  • 医院药局
  • 零售药局
  • 其他

第10章 市场洞察:各地区

  • 北美
    • 美国
    • 加拿大
    • 其他的北美
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 其他的欧洲
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他的亚太地区
  • 其他

第11章 支气管炎治疗市场动态

  • 推动市场要素
  • 市场课题
  • 影响分析

第12章 支气管炎治疗市场机会

第13章 支气管炎治疗市场趋势

第14章 需求与供给面的分析

  • 需求面分析
  • 供给面分析

第15章 价值链分析

第16章 竞争模式

  • 竞争情形
    • 波特的五力分析

第17章 公司概要

  • AstraZeneca PLC
  • Novartis AG
  • GlaxoSmithKline PLC
  • Dr. Reddy's Laboratories Ltd
  • Sanofi SA
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc.
  • Melinta Therapeutics
  • Lupin Limited
  • Cadila Healthcare Limited

第18章 免责声明

简介目录
Product Code: UMHE21863

The global bronchitis treatment market is expected to witness a CAGR of around 5% during the forecast period (2021-2027). The rising prevalence of respiratory diseases such as asthma, COPD, and lung cancer, among others coupled with rising geriatric population is expected to drive the demand for effective bronchitis treatment. According to the world health organization (WHO), around 262 million people suffer from asthma, and nearly 3 million people die from chronic obstructive pulmonary disease (COPD). Additionally, Bronchitis is when the tubes that carry air to your lungs, called the bronchial tubes, get inflamed and swollen.

AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Dr. Reddy's Laboratories Ltd, Sanofi SA, Boehringer Ingelheim International GmbH, Pfizer Inc., Melinta Therapeutics, Lupin Limited, Cadila Healthcare Limited Services are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report

"Amongst Type, Acute Bronchitis category to witness the fastest growth during the forecast period"

Based on type, the market is classified into acute bronchitis and chronic bronchitis. Amongst them, in 2020, the acute bronchitis category dominated the market and is expected to maintain its dominance throughout the forecast period. Acute bronchitis is an infectious viral infection that causes inflammation of the bronchial tubes. These tubes are the airways that carry air into your lungs. When these tubes get infected, they swell mucus (thick fluid) forms inside them. This narrows the airways, making it harder for breath-dependent patients. Furthermore, smoking is the main cause of chronic bronchitis. Therefore, an upsurge in the smoking populace is further expected to increase the need for bronchitis treatment. For instance, according to the Centers for Disease Control and Prevention (CDC), Nearly 40 million U.S. adults still smoke cigarettes, and an estimated 2.55 million middle and high school students use at least one tobacco product, including e-cigarettes.

"Amongst Drug Class, Bronchodilator category is expected to witness significant growth in the Bronchitis treatment market"

Based on drug class, the market is bifurcated into antibiotics, anti-inflammatory, bronchodilator, and others. Among them, in 2020, the bronchodilator category dominated the market and is expected to maintain its dominance throughout the forecast period. This is mainly due to the rising prevalence of chronic obstructive pulmonary disease (COPD), smoking, pollution, respiratory diseases, etc. According to the World health organization (WHO), Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, causing 3.23 million deaths in 2019.

"Amongst Distribution Channel, Hospitals Pharmacies category is expected to witness significant growth in the Bronchitis treatment market"

Based on distribution channel, the market is bifurcated into hospital pharmacies, retail pharmacies, and others. In 2020, the hospitals and clinics category accounted for the majority share during the forecast period. This can be ascribed to the fact that hospitals and clinics are the first step in any disease diagnosis. In addition, the growth of this market segment includes increased incidences of respiratory diseases, growth in the geriatric population, COPD, bronchitis, asthma, smoking, and rising air pollution all over the world. Additionally, smoking is the major reason for complications of bronchitis. Furthermore, according to the office of diseases prevention and health promotion (ODPHP), Currently, more than 25 million people in the United States have asthma. Approximately 14.8 million adults have been diagnosed with COPD, and approximately 12 million people have not yet been diagnosed. Furthermore, governments across the works are investing heavily in the development and improvement of healthcare infrastructure. Moreover, rising patient footfall in hospitals owing to ease of accessibility to most healthcare services in one place is likely to boost the segment growth.

"North America to witness significant growth during the forecast period"

For a better understanding of the market adoption of the Bronchitis treatment industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America); Europe (Germany, United Kingdom, France, Spain, Italy, Rest of Europe); Asia-Pacific (China, Japan, India, Rest of Asia-Pacific); and the Rest of World. In 2020. North America held an extensive market share owing to the increasing prevalence of respiratory diseases, growth in the geriatric population, COPD, bronchitis, asthma, smoking, and rising air pollution coupled with the rising geriatric population in the region. According to the US Census Bureau analysis, the elderly population is expected to nearly double in the next 25 years. In addition, according to World Population Ageing, in 2019, the elderly population of North America was 59.9 million which is expected to reach 96.2 million by 2050.

Reasons to buy this report:

  • The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
  • The report presents a quick review of overall industry performance at one glance.
  • The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolios, expansion strategies, and recent developments.
  • Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
  • The study comprehensively covers the market across different segments.
  • Deep dive regional level analysis of the industry.

Customization Options:

The Bronchitis treatment market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Limitation
  • 1.3. Stakeholders
  • 1.4. Currency used in Report

2 RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Bronchitis treatment Market
  • 2.2. Research Methodology of the Bronchitis treatment Market
  • 2.3. Forecasting Method
  • 2.4. Respondent Profile
  • 2.5. Main Objective of the Bronchitis treatment Market Study

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 BRONCHITIS TREATMENT MARKET COVID-19 IMPACT

6 BRONCHITIS TREATMENT MARKET REVENUE (USD BN), 2019-2027F

7 MARKET INSIGHTS BY TYPE

  • 7.1. Acute Bronchitis
  • 7.2. Chronic Bronchitis

8 MARKET INSIGHTS DRUG CLASS

  • 8.1. Antibiotics
  • 8.2. Anti-inflammatory
  • 8.3. Bronchodilator
  • 8.4. Others

9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

  • 9.1. Hospital Pharmacies
  • 9.2. Retail Pharmacies
  • 9.3. Others

10 MARKET INSIGHTS BY REGION

  • 10.1. North America
    • 10.1.1. U.S.
    • 10.1.2. Canada
    • 10.1.3. Rest of North America
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. United Kingdom
    • 10.2.3. France
    • 10.2.4. Spain
    • 10.2.5. Italy
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Rest of Asia-Pacific
  • 10.4. Rest of World

11 BRONCHITIS TREATMENT MARKET DYNAMICS

  • 11.1. Market Drivers
  • 11.2. Market Challenges
  • 11.3. Impact Analysis

12 BRONCHITIS TREATMENT MARKET OPPORTUNITIES

13 BRONCHITIS TREATMENT MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

  • 14.1. Demand Side Analysis
  • 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 COMPETITIVE SCENARIO

  • 16.1. Competitive Landscape
    • 16.1.1. Porter's Five Forces Analysis

17 COMPANY PROFILED

  • 17.1. AstraZeneca PLC
  • 17.2. Novartis AG
  • 17.3. GlaxoSmithKline PLC
  • 17.4. Dr. Reddy's Laboratories Ltd
  • 17.5. Sanofi SA
  • 17.6. Boehringer Ingelheim International GmbH
  • 17.7. Pfizer Inc.
  • 17.8. Melinta Therapeutics
  • 17.9. Lupin Limited
  • 17.10. Cadila Healthcare Limited

18 DISCLAIMER